22 Sept 2026Cipla Ltd Mr Venkata Sai Mungara ceases to be Senior Management Personnel effective 1 Oct 2026 due to transition to subsidiary roleKMP
3 Sept 2026Cipla Ltd announces exclusive strategic partnership with Qilu Pharmaceutical for licensing and supply of Keytruda biosimilar in the USMOU
3 Sept 2026Cipla Ltd intimation of NCLT order dated 18 Aug 2026 for Scheme of Amalgamation of Inzpera Healthsciences LimitedRestructuring
1 Sept 2026Cipla Ltd signs exclusive licensing agreement with SBP Group for HER2 bispecific ADC TQB2102 in India and emerging marketsMOU
31 Aug 2026Cipla Ltd signs exclusive licensing agreement with SBP Group for HER2 bispecific ADC TQB2102 development and commercialisation in India and other marketsMOU
27 Aug 2026Cipla Ltd discloses acquisition of 100% stake in Aspergen Inc., USA by its JV Aspergen Limited on 27 Aug 2026 to rationalise group structure.Restructuring
19 Aug 2026Cipla Ltd NCLT approves scheme of amalgamation of Inzpera Healthsciences Limited on 18 Aug 2026Restructuring
2 Jun 2026Cipla Limited newspaper advertisement for 90th Annual General Meeting scheduled on 25 June 2026 under Regulation 30Record Date
29 May 2026Cipla Limited Annual Secretarial Compliance Report for FY26 under Regulation 24A filed on 29 May, 2026Audit Reports
21 May 2026Cipla Ltd. record date announcement for FY26 final dividend under Regulation 30 scheduled on 5th June, 2026Record Date
13 May 2026Cipla Ltd. audited financial results and recommendation of final dividend for FY26 under Regulation 33 scheduled on 13 May, 2026Audit Reports
